Published on 24 Feb 2023 on Simply Wall St. via Yahoo Finance
Homology Medicines (NASDAQ:FIXX) shareholders have endured a 90% loss from investing in the stock...
As an investor, mistakes are inevitable. But really big losses can really drag down an overall portfolio. So take a moment to sympathize with the long term shareholders of Homology Medicines, Inc. (NASDAQ:FIXX), who have seen the share price tank a massive 90% over a three year period. That'd be enough to cause even the strongest minds some disquiet. The more recent news is of little comfort, with the share price down 42% in a year. On the other hand the share price has bounced 6.0% over the last week. We really hope anyone holding through that price crash has a diversified portfolio. Even when you lose money, you don't have to lose the lesson.
It's worthwhile assessing if the company's economics have been moving in lockstep with these underwhelming shareholder returns, or if there is some disparity between the two. So let's do just that.
Check out our latest analysis for Homology Medicines